| Record ID | marc_loc_2016/BooksAll.2016.part41.utf8:194868103:1700 |
| Source | Library of Congress |
| Download Link | /show-records/marc_loc_2016/BooksAll.2016.part41.utf8:194868103:1700?format=raw |
LEADER: 01700cam a2200337 i 4500
001 2014036257
003 DLC
005 20150129084438.0
008 140912s2015 flu b 001 0 eng
010 $a 2014036257
020 $a9781466561496 (hardback : alk. paper)
035 $a(DNLM)101641153
040 $aDNLM/DLC$cDLC$erda$dDLC
042 $apcc
050 00 $aR853.C55$bN42 2015
060 10 $aWA 950
082 00 $a615.5072/4$223
100 1 $aNg, Tie-Hua,$eauthor.
245 10 $aNoninferiority testing in clinical trials :$bissues and challenges /$cTie-Hua Ng.
264 1 $aBoca Raton :$bTaylor & Francis/CRC Press,$c[2015]
300 $axvii, 190 pages :$billustratons ;$c25 cm.
336 $atext$2rdacontent
337 $aunmediated$2rdamedia
338 $avolume$2rdacarrier
490 1 $aChapman & Hall/CRC biostatistics series
504 $aIncludes bibliographical references and index.
520 $a"This book focuses on the rationale of choosing the noninferiority (NI) margin as a small fraction of the therapeutic effect of the active control in a clinical trial. It discusses issues of estimating the effect size based on historical placebo control trials of the active control. The book also covers basic concepts related to NI trials, such as essay sensitivity, constancy assumption, discounting, and preservation. Other topics described include patient populations, three-arm trials, and testing equivalence of three or more groups"--Provided by publisher.
650 12 $aControlled Clinical Trials as Topic$xmethods.
650 12 $aData Interpretation, Statistical.
650 22 $aTherapeutic Equivalency.
830 0 $aChapman & Hall/CRC biostatistics series (Unnumbered)